Several treatment options specifically for HER2-positive breast cancer are available, including trastuzumab, pertuzumab, the antibody–drug conjugate ado-trastuzumab emtansine (T-DM1), and, more recently, trastuzumab deruxtecan and tucatinib. The gene discussed is ERBB2; the disease is breast carcinoma.